Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Sarah Cannon Research Institute, Nashville, TN, United States



Survival: 21.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Nashville, TN
   
Hospital: Sarah Cannon Research Institute
   
Journal: Link
   
Date: 8/2009

Description:
Patients:
This study involved 41 women with HER2-overexpressing metastatic breast cancer. The median age was 57 years (range 27-79).

Treatment:
The women in this study were given a combination of the chemotherapy agent gemcitabine and the biologic therapy agent trastuzumab, which is an antibody that targets the HER2 protein on cancer cells and leads to cell death.

Toxicities:
The most severe adverse events reported in this study were of grade 4 and included neutropenia (10% of patients), thrombocytopenia (2%), and anemia (2%). In addition, grade 3 nausea, fatigue, and alopecia were each reported by 17% of patients.

Results:
The median progression-free survival was 4 months and median overall survival was 21 months.

Support:
This study was supported by Eli Lilly and Genentech, makers of gemcitabine (trade name: Gemzar) and trastuzumab (trade name: Herceptin), respectively.

Correspondence: Dr. Denise Yardley; email: dyardley@tnonc.com

E-mail to a Friend Email Physician More Information